Liabilities and Equity of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly Liabilities and Equity in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Liabilities and Equity for the quarter ending 31 Dec 2025 was $530,922,000, a 42% increase year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $530,922,000 +$156,914,000 +42% 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $577,445,000 +$223,197,000 +63% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $326,076,000 -$42,883,000 -12% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $348,580,000 -$33,882,000 -8.9% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $374,008,000 +$194,603,000 +108% 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $354,248,000 +$161,786,000 +84% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $368,959,000 +$290,321,000 +369% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $382,462,000 +$299,021,000 +358% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $179,405,000 +$96,295,000 +116% 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $192,462,000 +$28,339,000 +17% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $78,638,000 -$96,483,000 -55% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $83,441,000 -$110,944,000 -57% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $83,110,000 +$73,659,000 +779% 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $164,123,000 -$42,113,000 -20% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $175,121,000 -$45,257,000 -21% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $194,385,000 +$49,765,000 +34% 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $9,451,000 -$152,168,000 -94% 31 Dec 2021 8-K 21 Dec 2023
Q3 2021 $206,236,000 +$31,595,000 +18% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $220,378,000 +$29,651,000 +16% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $144,620,000 +$179,000 +0.12% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $161,619,000 +$105,000 +0.06% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $174,641,000 -$2,592,000 -1.5% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $190,727,000 -$4,714,000 -2.4% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $144,441,000 -$3,251,000 -2.2% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $161,514,000 +$4,201,000 +2.7% 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q3 2019 $177,233,000 +$4,440,000 +2.6% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $195,441,000 +$14,823,000 +8.2% 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $147,692,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $157,313,000 +$102,850,000 +189% 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q3 2018 $172,793,000 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q2 2018 $180,618,000 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q4 2017 $54,463,000 31 Dec 2017 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.